Cargando…
Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—a phase 3 randomised trial
INTRODUCTION: There is a strong theoretical rationale for combining checkpoint blockade with cytotoxic chemotherapy in pleural mesothelioma and other cancers. Two recent single-arm, phase 2 trials [DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma (DREAM) and Phas...
Autores principales: | Kok, Peey Sei, Forde, Patrick M, Hughes, Brett, Sun, Zhuoxin, Brown, Chris, Ramalingam, Suresh, Cook, Alistair, Lesterhuis, Willem Joost, Yip, Sonia, O’Byrne, Ken, Pavlakis, Nick, Brahmer, Julie, Anagnostou, Valsamo, Ford, Kate, Fitzpatrick, Karen, Bricker, Alison, Cummins, Michelle M, Stockler, Martin, Nowak, Anna K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796233/ https://www.ncbi.nlm.nih.gov/pubmed/35078853 http://dx.doi.org/10.1136/bmjopen-2021-057663 |
Ejemplares similares
-
Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures
por: Rydzewski, Nicholas R., et al.
Publicado: (2021) -
Financial IncEntives for Smoking TreAtment: protocol of the FIESTA trial and FIESTA Oral Microbiome Substudy
por: French, Katherine M., et al.
Publicado: (2018) -
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
por: Forde, Patrick M., et al.
Publicado: (2021) -
Daily electronic self-monitoring of subjective and objective symptoms in bipolar disorder—the MONARCA trial protocol (MONitoring, treAtment and pRediCtion of bipolAr disorder episodes): a randomised controlled single-blind trial
por: Faurholt-Jepsen, Maria, et al.
Publicado: (2013) -
Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)
por: Smith, Deborah, et al.
Publicado: (2022)